Portfolio Lab

Incyte Corp

  • Stock
  • Ticker INCY
  • ISIN US45337C1027
  • Nasdaq

Health care · Biotechnology · USA

$114.63 −1.07%
Close of 20 Nov 2026
Open in backtest

Performance, volatility and drawdowns of Incyte Corp since 11/2016, with distributions reinvested and calculated in US dollars. As of 20 Nov 2026.

Performance

INCYGlobal equities (VT)

$10,000 grew to $10,604. Global equities (VT): $29,042.

Distributions reinvested, before taxes and brokerage costs. Dashed: Global equities (VT) for comparison.

Declines from the peak

Lowest point −66.5% in 04/2024, measured from the peak in 03/2017. The old peak has not been reached again yet.

1-year return
+12.6%
5-year return p.a.
+12.2%
10-year return p.a.
+0.6%
Volatility p.a.
30.0%
Largest decline
−66.5%

Financial statements

Amounts in $ millions from filings with the SEC, earnings per share in $; fourth quarter and quarterly cash flow derived from year-to-date figures

Quarter end12/202403/202506/202509/202512/202503/202606/202609/2026
Income statement
Revenue1,1791,0531,2161,3661,5071,2731,6741,557
Gross profit1,0909801,1371,2671,3861,1681,5691,448
Operating income302205530444336301698-708
EBITDA324228553468360325724-684
Net income201158405424299303586-785
Earnings per share0.950.802.042.111.461.472.81-3.86
Balance sheet
Total assets5,4445,7495,8216,3306,9587,3397,8737,287
Liabilities1,9972,0821,6501,6791,7901,7161,5281,644
Equity3,4483,6684,1714,6515,1675,6236,3445,643
Cash1,6881,9421,9552,4553,0983,4613,9823,276
Cash flow
Operating cash flow38126645559543369508-675
Free cash flow38126645559543369508-675

Value it:DCF calculatorMultiples calculator

Annual returns

Best year 2025 at +43.0%, weakest 2018 at −32.9%. 4 of 9 full years were positive. * partial year.

Quarterly reports

Filing date with the SEC and earnings per share of the quarter

DayEarnings per share
29 Oct 2026−$3.86
28 Jul 2026$2.81
28 Apr 2026$1.47
10 Feb 2026$1.46
28 Oct 2025$2.11
29 Jul 2025$2.04
29 Apr 2025$0.80
10 Feb 2025$0.95
29 Oct 2024$0.54
30 Jul 2024−$2.04
30 Apr 2024$0.75
13 Feb 2024$0.89

Key metrics

Metrics of 15 Nov 2026; P/E, P/B, P/S, market cap and dividend yield at the last close.

Valuation

Market cap
€21bn
Market cap in trading currency
$23.4bn
Enterprise value
$20.1bn
P/E
61.0
P/S
3.89
P/B
4.14
EV/Sales
3.34
EV/EBITDA
27.7
Earnings yield
1.6%
FCF yield
3.2%

Results (last four quarters)

Revenue
$6.01bn
Gross profit
$5.57bn
EBITDA
$725m
Net income
$403m
Earnings per share
$1.88
Revenue per share
$29.49
Revenue growth
+14.0%
Earnings growth
−285.0%

Profitability

Gross margin
92.7%
Operating margin
10.4%
Net margin
6.7%
Return on equity
7.8%
Return on assets
5.5%

Balance sheet and cash flow

Cash
$3.28bn
Cash per share
$16.07
Financial debt
–
Debt/equity %
–
Current ratio
3.84
Book value per share
$27.68
Operating cash flow
$745m
Free cash flow
$745m

Dividend

Dividend yield
0.00%
Dividend (12 months)
$0.00
Yield (12 months)
0.00%
Payout ratio
0%
Ex-dividend date
–

Shares and trading

Shares outstanding
204m
Volume
1.54m
Avg. volume 3 months
1.61m
Relative volume
0.9

Price and technicals

Price
$114.63
1 day
−1.1%
52-week high
$129.93
52-week low
$90.30
Distance to 52-week high
−11.8%
Distance to 52-week low
+26.9%
Distance to 50-day line
−3.3%
Distance to 200-day line
+4.9%
RSI (14)
42
Volatility 1M
31.6%

Performance

1 week
−5.2%
1 month
−2.0%
3 months
−10.4%
6 months
+18.0%
YTD
+16.1%
1 year
+13.1%

Dates

Fiscal year end
31 Dec 2025
Most recent quarter
30 Sep 2026

Frequently asked questions

How has INCY performed since 11/2016?

$10,000 grew to $10,604 by 20 Nov 2026, which is +0.6% per year. Distributions are reinvested; taxes and brokerage costs are not deducted.

How volatile is INCY?

Volatility was 30.0% per year, measured on monthly returns. The largest decline from a peak was −66.5%, with the low in 04/2024.

How does INCY compare with a broad equity ETF?

Over the same period Global equities (VT) returned +11.3% per year at 15.1% volatility, INCY returned +0.6% at 30.0%. The correlation of monthly returns was 0.38; 1 would mean they moved in lockstep.

Which currency are the figures in?

In US dollars, the currency of the US listing.

Not investment advice. Metrics and financial statements calculated from the company's mandatory filings with the SEC, without guarantee; amounts in US dollars.

Reference data of securities: source ESMA (FIRDS reference data) and SEC (EDGAR).

Not investment advice: results in Portfolio Lab are model calculations based on historical data and your inputs. Past performance is not a reliable indicator of future results.

Incyte Corp (INCY): Return and risk | Portfolio Lab